BioClinica Inc., a global specialty clinical trials services provider, has acquired Synowledge, a pharmaco-vigilance firm with offices in India and Japan, as part of its expansion strategy in Europe, Asia and the US. The details of the deal amount were not revealed by the company.
Synowledge is a specialized Pharmacovigilance, regulatory affairs and IT services provider to life sciences organizations with a team that consists of mostly doctors and pharma specialists.
Based in Newtown, Pennsylvania, BioClinica serves more than 400 pharmaceutical, biotechnology, and device organizations worldwide. BioClinica, with more than 400 pharma firms, is currently providing service to each of the world’s top 20 pharmaceutical companies and has important strategic relationships with the top 5 pharma majors in the world, including Daiichi-Sankyo, Roche, Baxter, Jazz, Biogen Idec, Merck Serono, Endo and Teva.
“This acquisition extends BioClinica’s solutions into an important new area for our customers,” said BioClinica President and Chief Executive Officer John Hubbard. Founded in 2006, Synowledge has excelled in providing pharmaco-vigilance services. It is engaged in monitoring and reporting adverse drug events which complements BioClinica’s technology-enabled services, he said.
Synowledge employs more than 500 people and the synergies with BioClinica go a long way, according to its founder CEO Sankesh Abhi. Sankesh Abbhi. ” Together, we offer customers a broader set of services and increased access to resources that support their overall drug development process,” he added.
Post-acquisition, Mr. Abbhi will serve as senior vice president and head of global safety and regulatory solutions and he will report to Mukhtar Ahmed, president of BioClinica’s eClinical Solutions Division.
BioClinica has three business segments — Medical Imaging and Biomarkers (626 employees), eClinical Solutions (318 employees) and Global Site Services (414 employees) which includes patient recruitment, a site network, and post approval services.
In July, BioClinica opened its new offices in London and Munich to expand its service base in Europe. John Hubbard, BioClinica’s CEO. said the European offices will focus on advanced image analysis for BioClinica’s extensive network of European radiologists and imaging specialists.